Preclinical inflammation studies often rely on biomarkers and histology, yet clinical success is defined by functional outcomes such as symptom relief or restored organ function. When this disconnect is not addressed early, programs risk advancing to the clinic without fully understanding therapeutic impact.
This webinar explores how incorporating functional readouts can better align preclinical endpoints with clinical expectations. Using atopic dermatitis and idiopathic pulmonary fibrosis as examples, we will highlight how endpoints such as itch and pulmonary function can be integrated to strengthen translational relevance.
We will also explore when functional readouts should be introduced within a program, and how their inclusion can reduce uncertainty and increase confidence in preclinical findings.
Join us to gain practical insight into designing studies that better reflect clinical reality across skin and lung disease models.
Key Learning Objectives
- Recognize common gaps between preclinical endpoints and clinical expectations in inflammatory disease research.
- Understand how reliance on biomarkers alone can limit successful translation to the clinic.
- Evaluate how functional readouts can increase clinical relevance and reduce late-stage risk.
- Apply study design strategies that better reflect clinical reality across skin and lung disease models.
